Pharmaceutical company Endo Inc (OTCQX: NDOI) announced Thursday the launch of ADRENALIN (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag, and will begin distribution from the week of 19 May 2025.
ADRENALIN is the first FDA-approved and currently only manufacturer-prepared epinephrine premixed IV bag on the market.
The ready-to-use product streamlines hospital operations by eliminating the need to prepare or transfer the product before patient administration, Endo said.
In addition, Endo offers ADRENALIN 4 mg/250 mL premixed bag and plans to launch 5 mg/250 mL and 10 mg/250 mL concentrations. The company also offers ADRENALIN (epinephrine injection, USP) 1 mL single-dose and 30 mL multi-dose vials.
ADRENALIN increases mean arterial blood pressure in adult patients with hypotension associated with septic shock.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval